Synonyms: Ro 67-31898/000 | Ro-673189000
netupitant is an approved drug (FDA (2014), EMA (2015))
Compound class:
Synthetic organic
Comment: Netupitant is a selective tachykinin receptor 1 (NK1) receptor antagonist.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖![]() View more information in the IUPHAR Pharmacology Education Project: netupitant |
|
No information available. |
Summary of Clinical Use ![]() |
Netupitant is approved as a component of the fixed-dose drug Akynzeo®, the other component being palonosetron. This orally administered drug mixture is a prophylactic used to provide supportive care for patients receiving emetogenic chemotherapy, and is superior in action to palonosetron alone [1]. In April 2018 the FDA approved a modified formulation of Akynzeo® that is designed for i.v. infusion, and contains fosnetupitant (phosphorylated netupitant; PubChem CID 71544786) in place of netupitant. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Netupitant is an antagonist of the neurokinin type 1 receptor (NK1) and palonosetron is a serotonin 5-HT3 receptor antagonist. These compounds act together to inhibit pathways involved in emesis [1]. |
External links ![]() |
For extended ADME data see the following: European Medicines Agency (EMA) |